Dr Sophie Whyte

All publications

Journal articles

• Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) MA10.05 Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review. Journal of Thoracic Oncology, 18(11), S134-S134.
• Whyte S, Thomas C, Chilcott J & Kearns B (2022) Optimizing the design of a repeated fecal immunochemical test bowel cancer screening programme with a limited endoscopy capacity from a health economic perspective. Value in Health, 25(6), 954-964.
• Thomas C, Mandrik O, Saunders CL, Thompson D, Whyte S, Griffin S & Usher-Smith JA (2021) The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis. Cancer Prevention Research, 14(8), 811-822. View this article in WRRO
• Rubin G, Walter FM, Emery J, Hamilton W, Hoare Z, Howse J, Nixon C, Srivastava T, Thomas C, Ukoumunne OC , Usher-Smith JA et al (2021) Electronic clinical decision support tool for assessing stomach symptoms in primary care (ECASS): a feasibility study. BMJ Open, 11(3). View this article in WRRO
• Rutter MD, Bretthauer M, Hassan C, Jover R, Adami H-O, Corley DA, Cubiella J, Cross AJ, Evelien Dekker PD, Gupta S , Kalager M et al (2020) Principles for Evaluation of Surveillance After Removal of Colorectal Polyps: Recommendations From the World Endoscopy Organization. Gastroenterology, 158(6), 1529-1533.e4.
• Rutter MD, East J, Rees CJ, Cripps N, Docherty J, Dolwani S, Kaye PV, Monahan KJ, Novelli MR, Plumb A , Saunders BP et al (2019) British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. Gut, 69(2), 201-223. View this article in WRRO
• Thomas C, Whyte S, Kearns B & Chilcott JB (2019) External Validation of a Colorectal Cancer Model Against Screening Trial Long-Term Follow-Up Data. Value in Health, 22(10), 1154-1161. View this article in WRRO
• Kearns B, Chilcott J, Relton C, Whyte S, Woods HB, Nickerson C & Loban A (2018) The association between long-term conditions and uptake of population-based screening for colorectal cancer: results from two English cohort studies. Cancer Management and Research, 10, 637-645. View this article in WRRO
• Picot J, Rose M, Cooper K, Pickett K, Lord J, Harris P, Whyte S, Böhning D & Shepherd J (2017) Virtual chromoendoscopy for the real-time assessment of colorectal polyps in vivo: a systematic review and economic evaluation.. Health Technology Assessment, 21(79), 1-308. View this article in WRRO
• Ren S, Minton J, Whyte S, Latimer N & Stevenson M (2017) A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis. PharmacoEconomics. View this article in WRRO
• Uttley L, Whyte S, Gomersall T, Ren S, Wong R, Chambers D & Tappenden P (2017) Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics, 35(7), 717-726. View this article in WRRO
• Faria R, Walker S, Whyte S, Dixon S, Palmer S & Sculpher M (2017) How to Invest in Getting Cost-effective Technologies into Practice? A Framework for Value of Implementation Analysis Applied to Novel Oral Anticoagulants. Medical Decision Making, 37(2), 148-161.
• Kearns B, Chilcott J, Whyte S, Preston L & Sadler S (2017) Erratum to: Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Medicine, 15(1).
• Kearns B, Chilcott J, Whyte S, Preston L & Sadler S (2016) Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation. BMC Medicine, 14(1), 200-200. View this article in WRRO
• Moore HJ, Nixon C, Tariq A, Emery J, Hamilton W, Hoare Z, Kershenbaum A, Neal RD, Ukoumunne OC, Usher-Smith J , Walter FM et al (2016) Evaluating a computer aid for assessing stomach symptoms (ECASS): study protocol for a randomised controlled trial. Trials, 17(1). View this article in WRRO
• Whyte S, Dixon S, Faria R, Walker S, Palmer S, Sculpher M & Radford S (2016) Estimating the Cost-Effectiveness of Implementation: Is Sufficient Evidence Available?. Value in Health, 19(2), 138-144. View this article in WRRO
• Kearns B, Whyte S, Seaman HE, Snowball J, Halloran SP, Butler P, Patnick J, Nickerson C & Chilcott J (2016) Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm. British Journal of Cancer, 114(3), 327-333. View this article in WRRO
• Rowen D, Brazier J, Mukuria C, Keetharuth A, Risa Hole A, Tsuchiya A, Whyte S & Shackley P (2016) Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life. Medical Decision Making, 36(2), 210-222.
• Hinde S, McKenna C, Whyte S, Peake MD, Callister MEJ, Rogers T & Sculpher M (2015) Modelling the cost-effectiveness of public awareness campaigns for the early detection of non-small-cell lung cancer. British Journal of Cancer, 113(1), 135-141. View this article in WRRO
• Asaria M, Griffin S, Cookson R, Whyte S & Tappenden P (2015) Distributional Cost-Effectiveness Analysis of Health Care Programmes - A Methodological Case Study of the UK Bowel Cancer Screening Programme. Health Economics, 24(6), 742-754.
• Kearns B, Whyte S, Chilcott J & Patnick J (2014) Guaiac faecal occult blood test performance at initial and repeat screens in the English Bowel Cancer Screening Programme. British Journal of Cancer, 111(9), 1734-1741. View this article in WRRO
• Whyte S & Harnan S (2014) Effectiveness and cost-effectiveness of an awareness campaign for colorectal cancer: a mathematical modeling study.. Cancer Causes Control, 25(6), 647-658. View this article in WRRO
• Asaria M, Griffin S, Cookson R, Tappenden P & Whyte S (2013) A FRAMEWORK FOR THE COST-EQUALITY ANALYSIS OF HEALTH CARE PROGRAMMES. VALUE IN HEALTH, 16(7), A426-A426.
• Sharp L, Tilson L, Whyte S, Ceilleachair AO, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2013) Using resource modelling to inform decision making and service planning: the case of colorectal cancer screening in Ireland.. BMC Health Serv Res, 13, 105. View this article in WRRO
• Sharp L, Walsh C, Whyte S, Tilson L, O'Ceilleachair A, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2013) Reply: cost-effectiveness of population-based screening for colorectal cancer. British Journal of Cancer, 108(5), 1211-1212.
• Whyte S, Pandor A & Stevenson M (2012) Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.. Pharmacoeconomics, 30(12), 1119-1132.
• Whyte S, Chilcott J & Halloran S (2012) Reappraisal of the options for colorectal cancer screening in England.. Colorectal Dis, 14(9), e547-e561.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Barry M & Comber H (2012) Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy.. Br J Cancer, 106(5), 805-816. View this article in WRRO
• Tilson L, Sharp L, Usher C, Walsh C, Whyte S, O'Ceilleachair A, Stuart C, Mehigan B, Kennedy MJ, Tappenden P , Chilcott J et al (2012) Cost of care for colorectal cancer in Ireland: A health care payer perspective. European Journal of Health Economics, 13(4), 511-524.
• Madan J, Stevenson MD, Cooper KL, Ades AE, Whyte S & Akehurst R (2011) Consistency between direct and indirect trial evidence: is direct evidence always more reliable?. Value Health, 14(6), 953-960. View this article in WRRO
• Whyte S, Cooper KL, Stevenson MD, Madan J & Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.. Value Health, 14(4), 465-474.
• Cooper KL, Madan J, Whyte S, Stevenson MD & Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis. BMC Cancer, 11. View this article in WRRO
• Whyte S, Walsh C & Chilcott J (2011) Bayesian Calibration of a Natural History Model with Application to a Population Model for Colorectal Cancer. Medical Decision Making, 31(4), 625-641.
• Whyte S, Pandor A, Stevenson M & Rees A (2010) Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.. Health Technol Assess, 14(Suppl. 2), 47-53. View this article in WRRO
• Whyte S, Walsh C, Sharp L, O'Ceilleachair A, Tilson L, Usher C, Chilcott J, Tappenden P, Staines A, Comber H & Barry M (2009) PMC46 BAYESIAN CALIBRATION OF A NATURAL HISTORY MODEL FOR COLORECTAL CANCER. Value in Health, 12(7), A395-A395.
• Sharp L, Tilson L, Whyte S, O'Ceilleachair A, Walsh C, Usher C, Tappenden P, Chilcott J, Staines A, Comber H & Barry M (2009) COST-EFFECTIVENESS OF A POPULATION-BASED COLORECTAL CANCER SCREENING PROGRAMME IN IRELAND. VALUE HEALTH, 12(7), A280-A280.
• Harnan S, Hamilton J, Simpson E, Clowes M, Navega Biz A, Whyte S, Ren S, Cooper K, Abulafi M, Ball A , Beton S et al () Faecal Immunochemical Tests For Patients With Symptoms Suggestive Of Colorectal Cancer: An Updated Systematic Review And Multiple-Threshold Meta-Analysis of Diagnostic Test Accuracy Studies. Colorectal Disease.
• Thomas C, Mandrik O & Whyte S () Modelling cost-effective strategies for minimising socioeconomic inequalities in colorectal cancer screening outcomes in England. Preventive Medicine.
• Thomas C, Mandrik O, Whyte S, Saunders CL, Griffin SJ & Usher‐Smith JA () Should colorectal cancer screening start at different ages for men and women? Cost‐effectiveness analysis for a resource‐constrained service. Cancer Reports. View this article in WRRO
• Whyte S, Pandor A, Stevenson M & Rees A () Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. Health Technology Assessment, 14(Suppl 2), 47-53.
• Mandrik O, Thomas C, Whyte S & Chilcott J () CALIBRATING NATURAL HISTORY OF CANCER MODELS IN THE PRESENCE OF DATA INCOMPATIBILITY; PROBLEMS AND SOLUTIONS. PharmacoEconomics.

Conference proceedings papers

• Needham KJ, Tappenden P, Gillespie D & Whyte S (2023) Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review. JOURNAL OF THORACIC ONCOLOGY, Vol. 18(11) (pp S134-S134)
• Kearns B, Chilcott & whyte (2016) Flexible parametric survival models and time-series analysis for extrapolating time-varying treatment effects in health technology assessment. Flexible parametric survival models and time-series analysis for extrapolating time-varying treatment effects in health technology assessment, 5 September 2016 - 8 September 2016.
• Faria R, Walker S, Whyte S, Dixon S, Sculpher M & Palmer S (2015) The value of implementation: how to invest in getting cost-effective technologies into practice. Framework and application to novel oral anticoagulants in the prevention of stroke and systemic embolism. HESG. Leeds
• Faria R, Whyte S, Palmer S & Hoomans T (2014) WORKSHOP 2999: From evaluation to implementation: how to ensure efficient investment in implementation of cost-effective technologies in clinical practice?. ISPOR. Amsterdam, 9 November 2014 - 12 November 2014.
• Rowen D, Brazier J, Mukuria C, Whyte S, Keetharuth A, Risa Hole A, Tsuchiya A & Shackley P (2014) Rowen D, Brazier J, Mukuria C, Whyte S, Keetharuth A, Risa Hole A, Tsuchiya A, Shackley P. Eliciting societal preferences for burden of illness, therapeutic improvement and end of life for value based pricing.. HESG. Sheffield, UK, 8 January 2014.
• Asaria M, Griffin S, Cookson R, Whyte S & Tappenden P (2013) A framework for the cost-equality analysis of health care programmes. ISPOR. Dublin
• Bessey A, Whyte S, Minton J & Chilcott J (2013) Economic evaluation of an electrical impedance spectroscopy (EIS) device used as an adjunct to colposcopy. VALUE IN HEALTH, Vol. 16(7) (pp A407-A407)
• Whyte S (2013) Cost effectiveness analysis of an early awareness campaign for colorectal cancer. Cancer Outcomes Conference. Brighton
• Whyte S (2013) Effectiveness and cost effectiveness of an awareness campaign for colorectal cancer: A mathematical modelling study. Cancer Research UK NAEDI conference. Cambridge, UK
• Whyte S (2012) The cost effectiveness of an early awareness campaign for colorectal cancer. SMDM. Oslo, Norway, 10 June 2012 - 12 June 2012.
• Whyte S, Scope A & Tappenden P (2012) The cost effectiveness of an early awareness campaign for colorectal cancer. SMDM. Oslo, Norway
• Whyte S & Chilcott J (2010) Using a natural history model in combination with screening data to estimate the test characteristics of the FOB test in the English bowel cancer screening programme. Methods for evaluating medical tests and biomarkers. Birmingham, UK
• Whyte S (2009) Bayesian calibration of a natural history model for colorectal cancer. ISPOR. Paris
• Whyte S, Dixon S, Faria R, Walker S, Sculpher M & Palmer S () The value of investing implementation activities: A case study in natriuretic peptide testing for diagnosing suspected heart failure (2014)

Reports

• Srivastava T, Chambers D, Thomas C & Whyte S (2019) ECASS health economic feasibility study View this article in WRRO
• Whyte S, Thomas C, Kearns B, Webster M & Chilcott J (2017) Optimising Bowel Cancer Screening Phase 1: Optimising the cost effectiveness of repeated FIT screening and screening strategies combining bowel scope and FIT screening View this article in WRRO
• Pollard D, Cree I & Whyte S (2016) Generic Cancer Screen - Economic modelling report View this article in WRRO
• Whyte S, Chambers D & Wong R (2015) Degarelix for treating advanced hormone-dependent Prostate cancer [ID590] Spinal cord compression associated with hormonal therapy in men with hormone-dependent metastatic prostate cancer: a systematic review and economic assessment
• Faria R, Walker S, Whyte S, Dixon S, Palmer S & Sculpher M (2014) Getting cost-effective technologies into practice: the value of implementation An application to novel anticoagulants in the prevention of stroke and systemic embolism
• Whyte S, Dixon S, Faria R, Walker S, Palmer S & Sculpher M (2014) Getting cost-effective technologies into practice: the value of implementation. An application to B-type natriuretic peptide (BNP) testing in diagnosing chronic heart failure View this article in WRRO
• Walker S, Faria R, Whyte S, Dixon S, Palmer S & Sculpher M (2014) Getting cost-effective technologies into practice: the value of implementation. Report on framework for valuing implementation initiatives
• Rowen D, Brazier J, Mukuria C, Keetharuth A, Rise Hole A, Tsuchiya A, Whyte S & Shackley P (2014) Update: Eliciting societal preferences for weighting QALY's according to burden of illness, size of gain and end of life View this article in WRRO
• Whyte S, Brazier J, Rowen D, Mukuria C, Keetharuth A, RiseHole A, Tsuchiya A & Shackley P (2013) Eliciting societal preferences for burden of illness, therapeutic improvement and end of life for value based pricing: a report of the main survey View this article in WRRO
• Hinde S, McKenna C, Whyte S, Peake M, Callister M, Rogers T & Sculpher M (2012) Modelling the cost-effectiveness of early awareness interventions for the early detection of lung cancer
• Whyte S, Harnan S, Scope A, Simpson E, Tappenden P, Duffy S, Rachet B, Sculpher M, Hinde S, McKenna C & Wong R (2012) Early awareness interventions for cancer: Colorectal cancer View this article in WRRO
• Whyte S, Cooper KL, Stevenson MD, Madan J & Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom
• Whyte S, Cooper KL, Stevenson MD & Akehurst R (2011) Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in patients with non-Hodgkin's lymphoma in the United Kingdom (UK)
• Whyte S, Chilcott J, Essat M, Stevens J, Wong R & Kalita N (2011) Reappraisal of the options for colorectal cancer screening View this article in WRRO
• Madan J, Cooper KL, Stevenson MD, Whyte S & Akehurst R (2009) Consistency between direct trial evidence and Bayesian Mixed Treatment Comparison: Is head-to-head evidence always more reliable?
• Cooper KL, Madan J, Whyte S, Stevenson MD & Akehurst R (2009) Granulocyte colony-stimulating factors for prevention of febrile neutropenia following chemotherapy: systematic review and meta-analysis
• Sharp L, Whyte S, Ceillachair A, Comber H, Tilson L, Usher C, Walsh C, Barry M, Tappenden P, Chilcott J & Staines A (2009) Options for a population-based colorectal cancer screening programme in Ireland: a health technology assessment
• Whyte S, Chilcott J & Headley J (2008) Health economics of Colonix: A new diagnostic test in colorectal cancer

Posters

• Whyte S, Dixon S, Faria R, Walker S, Sculpher M & Palmer S The value of investing in implementation activities: A case study in natriuretic peptide testing for diagnosing suspected heart failure (SMDM 15th Biennial European Meeting 8-10 June 2015).

Preprints

• Mandrik O, Thomas C, Strong M & Whyte S (2021) Calibration and Validation of the Microsimulation Model in Cancer of the Bowel (MiMiC-Bowel), an Individual Patient Simulation Model for Investigation of the Cost-effectiveness of Personalised Screening and Surveillance Strategies.. View this article in WRRO